TSHA FY 2022 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$14,9990.6% margin

Operating Income

-$126M-5037.1% margin

Net Income

-$166M-6635.3% margin

EPS (Diluted)

$-3.78

Cash Flow

Operating Cash Flow

-$88M

Free Cash Flow

-$113M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$126M

Total Liabilities

$125M

Stockholders' Equity

$949,000

Cash & Equivalents

$88M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$14,999	$0	—
Operating Income	-$126M	-$173M	+27.3%
Net Income	-$166M	-$175M	+4.9%